Compound ID | 3470
Synonym(s): Irgasan DP300, Irgacare MP
Class: Synthetic small molecule antibacterial agent
Spectrum of activity: | Gram-positive & Gram-negative |
Details of activity: | Broad-spectrum activity; lipid synthesis inhibitor/ fatty acid synthesis inhibitor (FabI inhibitor) |
Description: | Synthetic compound; initially approved as additive for oral and skin care products |
Institute where first reported: | Ciba-Geigy Company, Basel, Switzerland |
Year first mentioned: | 1964 |
Highest developmental phase: | Approved by FDA in 1997 |
Development status: | Discontinued |
Reason Dropped: | Widespread environmental dissemination and its recalcitrant nature is thought to amplify distribution of resistance genes; long-term effects could pose health risks |
Chemical structure(s): | |||||||||||
|
|